Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 272

1.

Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.

Ganne-Carrié N, Chaffaut C, Bourcier V, Archambeaud I, Perarnau JM, Oberti F, Roulot D, Moreno C, Louvet A, Dao T, Moirand R, Goria O, Nguyen-Khac E, Carbonell N, Antonini T, Pol S, de Ledinghen V, Ozenne V, Henrion J, Péron JM, Tran A, Perlemuter G, Amiot X, Zarski JP, Beaugrand M, Chevret S; for CIRRAL Group.

J Hepatol. 2018 Dec;69(6):1274-1283. doi: 10.1016/j.jhep.2018.07.022. Epub 2018 Aug 6.

2.

Capillary microfluidics in microchannels: from microfluidic networks to capillaric circuits.

Olanrewaju A, Beaugrand M, Yafia M, Juncker D.

Lab Chip. 2018 Aug 7;18(16):2323-2347. doi: 10.1039/c8lc00458g. Review.

PMID:
30010168
3.

Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement.

Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Lee HW, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J.

Aliment Pharmacol Ther. 2018 Apr;47(7):989-1000. doi: 10.1111/apt.14529. Epub 2018 Feb 15.

4.

Metal Binding Properties of the N-Terminus of the Functional Amyloid Orb2.

Bajakian TH, Cervantes SA, Soria MA, Beaugrand M, Kim JY, Service RJ, Siemer AB.

Biomolecules. 2017 Aug 1;7(3). pii: E57. doi: 10.3390/biom7030057.

5.

Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan.

Roulot D, Roudot-Thoraval F, NKontchou G, Kouacou N, Costes JL, Elourimi G, Le Clesiau H, Ziol M, Beaugrand M.

Liver Int. 2017 Dec;37(12):1897-1906. doi: 10.1111/liv.13481. Epub 2017 Jul 2.

PMID:
28556413
6.

Comparative study of the structure and interaction of the pore helices of the hERG and Kv1.5 potassium channels in model membranes.

Beaugrand M, Arnold AA, Bourgault S, Williamson PTF, Marcotte I.

Eur Biophys J. 2017 Sep;46(6):549-559. doi: 10.1007/s00249-017-1201-2. Epub 2017 Mar 17.

PMID:
28314880
7.

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.

Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J.

J Hepatol. 2017 May;66(5):1022-1030. doi: 10.1016/j.jhep.2016.12.022. Epub 2016 Dec 28.

PMID:
28039099
8.

Magnetically Oriented Bicelles with Monoalkylphosphocholines: Versatile Membrane Mimetics for Nuclear Magnetic Resonance Applications.

Beaugrand M, Arnold AA, Juneau A, Gambaro AB, Warschawski DE, Williamson PT, Marcotte I.

Langmuir. 2016 Dec 13;32(49):13244-13251. Epub 2016 Nov 28.

PMID:
27951690
9.

Hepatocellular Carcinoma within Milan Criteria: No-Touch Multibipolar Radiofrequency Ablation for Treatment-Long-term Results.

Seror O, N'Kontchou G, Nault JC, Rabahi Y, Nahon P, Ganne-Carrié N, Grando V, Zentar N, Beaugrand M, Trinchet JC, Diallo A, Sellier N.

Radiology. 2016 Sep;280(3):981. doi: 10.1148/radiol.2016164017. No abstract available.

PMID:
27533029
10.

Hepatocellular Carcinoma within Milan Criteria: No-Touch Multibipolar Radiofrequency Ablation for Treatment-Long-term Results.

Seror O, N'Kontchou G, Nault JC, Rabahi Y, Nahon P, Ganne-Carrié N, Grando V, Zentar N, Beaugrand M, Trinchet JC, Diallo A, Sellier N.

Radiology. 2016 Aug;280(2):611-21. doi: 10.1148/radiol.2016150743. Epub 2016 Mar 24. Erratum in: Radiology. 2016 Sep;280(3):981.

PMID:
27010381
11.

Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B.

Cardoso AC, Beaugrand M, de Ledinghen V, Douvin C, Poupon R, Trinchet JC, Ziol M, Bedossa P, Marcellin P.

Ann Hepatol. 2015 Nov-Dec;14(6):826-36. doi: 10.5604/16652681.1171762.

12.

Prevalence and clinical significance of nodular regenerative hyperplasia in liver biopsies.

Barge S, Grando V, Nault JC, Broudin C, Beaugrand M, Ganne-Carrié N, Roulot D, Ziol M.

Liver Int. 2016 Jul;36(7):1059-66. doi: 10.1111/liv.12974. Epub 2015 Oct 19.

PMID:
26415006
13.

Inflammation-adapted liver stiffness values for improved fibrosis staging in patients with hepatitis C virus and alcoholic liver disease.

Mueller S, Englert S, Seitz HK, Badea RI, Erhardt A, Bozaari B, Beaugrand M, Lupșor-Platon M.

Liver Int. 2015 Dec;35(12):2514-21. doi: 10.1111/liv.12904. Epub 2015 Jul 30.

PMID:
26121926
14.

Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma.

Ganne-Carrié N, Nault JC, Ziol M, N'Kontchou G, Nahon P, Grando V, Bourcier V, Barge S, Beaugrand M, Trinchet JC, Seror O.

Hepat Oncol. 2014 Oct;1(4):395-408. doi: 10.2217/hep.14.22. Epub 2014 Dec 11. Review.

15.

Lipid concentration and molar ratio boundaries for the use of isotropic bicelles.

Beaugrand M, Arnold AA, Hénin J, Warschawski DE, Williamson PT, Marcotte I.

Langmuir. 2014 Jun 3;30(21):6162-70. doi: 10.1021/la5004353. Epub 2014 May 19.

16.

Impact of cytokine gene variants on the prediction and prognosis of hepatocellular carcinoma in patients with cirrhosis.

Tarhuni A, Guyot E, Rufat P, Sutton A, Bourcier V, Grando V, Ganne-Carrié N, Ziol M, Charnaux N, Beaugrand M, Moreau R, Trinchet JC, Mansouri A, Nahon P.

J Hepatol. 2014 Aug;61(2):342-50. doi: 10.1016/j.jhep.2014.04.011. Epub 2014 Apr 18.

PMID:
24751829
17.

High frequency of X chromosome abnormalities in women with short stature and elevated liver enzymes.

Roulot D, Malan V, Ziol M, Linglart A, Bourcier V, Beaugrand M, Benzacken B.

J Clin Endocrinol Metab. 2014 Aug;99(8):E1592-6. doi: 10.1210/jc.2014-1037. Epub 2014 Apr 14.

PMID:
24731013
18.

Histopathologic comparison of monopolar versus no-touch multipolar radiofrequency ablation to treat hepatocellular carcinoma within Milan criteria.

Seror O, N'Kontchou G, Van Nhieu JT, Rabahi Y, Nahon P, Laurent A, Trinchet JC, Cherqui D, Vicaut E, Beaugrand M, Sellier N.

J Vasc Interv Radiol. 2014 Apr;25(4):599-607. doi: 10.1016/j.jvir.2013.11.025. Epub 2014 Feb 12.

PMID:
24529547
19.

Single-channel electrophysiology of cell-free expressed ion channels by direct incorporation in lipid bilayers.

Friddin MS, Smithers NP, Beaugrand M, Marcotte I, Williamson PT, Morgan H, de Planque MR.

Analyst. 2013 Nov 12;138(24):7294-8. doi: 10.1039/c3an01540h.

PMID:
24162163
20.

ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma.

Ziol M, Sutton A, Calderaro J, Barget N, Aout M, Leroy V, Blanc JF, Sturm N, Bioulac-Sage P, Nahon P, Nault JC, Charnaux N, N'kontchou G, Trinchet JC, Delehedde M, Seror O, Beaugrand M, Vicaut E, Ganne-Carrié N.

J Hepatol. 2013 Dec;59(6):1264-70. doi: 10.1016/j.jhep.2013.07.030. Epub 2013 Aug 6.

PMID:
23928407
21.

Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis.

Nault JC, Guyot E, Laguillier C, Chevret S, Ganne-Carrie N, N'Kontchou G, Beaugrand M, Seror O, Trinchet JC, Coelho J, Lasalle P, Charnaux N, Delehedde M, Sutton A, Nahon P.

Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1343-52. doi: 10.1158/1055-9965.EPI-13-0179. Epub 2013 Jun 18.

22.

Stakeholder perspectives on European priorities for comprehensive liver cancer control: a conjoint analysis.

Joy SM, Blauvelt BM, Tuncer MA, Beaugrand M, Sangro B, Colombo M, Bridges JF.

Eur J Public Health. 2013 Dec;23(6):951-7. doi: 10.1093/eurpub/cks173. Epub 2013 Mar 26.

PMID:
23531524
23.

Severe hepatitis induced by cyproterone acetate: role of corticosteroids. A case report.

Abenavoli L, Milic N, Beaugrand M.

Ann Hepatol. 2013 Jan-Feb;12(1):152-5.

24.

[Hepatocellular carcinoma: risk factors and screening].

Beaugrand M, N'kontchou G.

Bull Acad Natl Med. 2012 Jan;196(1):85-94; discussion 94-6. French.

PMID:
23259336
25.

Diaphragmatic necrosis after radiofrequency ablation of hepatocellular carcinoma: a successful surgical repair.

Kanso F, Nahon P, Blaison D, Trinchet JC, Beaugrand M, Seror O, Martinod E.

Clin Res Hepatol Gastroenterol. 2013 Apr;37(2):e59-63. doi: 10.1016/j.clinre.2012.09.011. Epub 2012 Nov 6.

PMID:
23137756
26.

Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis.

Nahon P, Amathieu R, Triba MN, Bouchemal N, Nault JC, Ziol M, Seror O, Dhonneur G, Trinchet JC, Beaugrand M, Le Moyec L.

Clin Cancer Res. 2012 Dec 15;18(24):6714-22. doi: 10.1158/1078-0432.CCR-12-1099. Epub 2012 Nov 7.

27.

Peripheral intrahepatic cholangiocarcinoma occurring in patients without cirrhosis or chronic bile duct diseases: epidemiology and histopathology of distant nontumoral liver in 57 White patients.

Nkontchou G, Tran Van Nhieu J, Ziol M, Tengher I, Mahmoudi A, Roulot D, Bourcier V, Ganne Carrie N, Grando-Lemaire V, Trinchet JC, Cherqui D, Beaugrand M.

Eur J Gastroenterol Hepatol. 2013 Jan;25(1):94-8. doi: 10.1097/MEG.0b013e328357cdd7.

PMID:
23085575
28.

Keratin 8 variants are infrequent in patients with alcohol-related liver cirrhosis and do not associate with development of hepatocellular carcinoma.

Usachov V, Nahon P, Lunova M, Ziol M, Rufat P, Sutton A, Beaugrand M, Strnad P.

BMC Gastroenterol. 2012 Oct 18;12:147. doi: 10.1186/1471-230X-12-147.

29.

PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.

Guyot E, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, Ganne-Carrié N, Beaugrand M, Charnaux N, Trinchet JC, Nahon P.

J Hepatol. 2013 Feb;58(2):312-8. doi: 10.1016/j.jhep.2012.09.036. Epub 2012 Oct 13.

PMID:
23069476
30.

Insulin-like growth factor 2 gene methylation in peripheral blood mononuclear cells of patients with hepatitis C related cirrhosis or hepatocellular carcinoma.

Couvert P, Carrié A, Tezenas du Montcel S, Vaysse J, Sutton A, Barget N, Trinchet JC, Beaugrand M, Ganne N, Giral P, Chelly J.

Clin Res Hepatol Gastroenterol. 2012 Aug;36(4):345-51. doi: 10.1016/j.clinre.2012.06.013. Epub 2012 Aug 16.

PMID:
22902352
31.

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM.

J Hepatol. 2012 Oct;57(4):821-9. doi: 10.1016/j.jhep.2012.06.014. Epub 2012 Jun 19.

32.

Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis.

Nkontchou G, Aout M, Mahmoudi A, Roulot D, Bourcier V, Grando-Lemaire V, Ganne-Carrie N, Trinchet JC, Vicaut E, Beaugrand M.

Cancer Prev Res (Phila). 2012 Aug;5(8):1007-14. doi: 10.1158/1940-6207.CAPR-11-0450. Epub 2012 Apr 23.

33.

Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C.

Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, Poupon R, Cardoso AC, Marcellin P, Douvin C, de Ledinghen V, Trinchet JC, Beaugrand M.

J Viral Hepat. 2012 Apr;19(4):244-53. doi: 10.1111/j.1365-2893.2011.01534.x. Epub 2011 Oct 13.

PMID:
22404722
34.

Transient elastography in non-alcoholic fatty liver disease.

Abenavoli L, Beaugrand M.

Ann Hepatol. 2012 Mar-Apr;11(2):172-8. Review.

35.

[Results of percutaneous radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis aged 75 years and over].

Lahbabi M, N'kontchou G, Aout M, Vicaud E, Ganne N, Trinchet JC, Seror O, Beaugrand M.

Rev Med Interne. 2012 Mar;33(3):128-33. doi: 10.1016/j.revmed.2011.12.002. Epub 2012 Jan 4. French.

PMID:
22226387
36.

Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities.

Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, Roulot D, Mallat A, Hillaire S, Cales P, Ollivier I, Vinel JP, Mathurin P, Bronowicki JP, Vilgrain V, N'Kontchou G, Beaugrand M, Chevret S; Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH).

Hepatology. 2011 Dec;54(6):1987-97. doi: 10.1002/hep.24545.

PMID:
22144108
37.

A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria.

Seror O, N'Kontchou G, Ganne N, Beaugrand M.

Ann Surg. 2011 Nov;254(5):837; author reply 837-8. doi: 10.1097/SLA.0b013e318235e4eb. No abstract available.

PMID:
21997808
38.

The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan.

Sasso M, Miette V, Sandrin L, Beaugrand M.

Clin Res Hepatol Gastroenterol. 2012 Feb;36(1):13-20. doi: 10.1016/j.clinre.2011.08.001. Epub 2011 Sep 15. Review.

PMID:
21920839
39.

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis.

Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, Roulot D, Ganne-Carrie N, Grando-Lemaire V, Trinchet JC, Gordien E, Vicaut E, Baghad I, Beaugrand M.

J Viral Hepat. 2011 Oct;18(10):e516-22. doi: 10.1111/j.1365-2893.2011.01441.x.

PMID:
21914071
40.

A variant in myeloperoxidase promoter hastens the emergence of hepatocellular carcinoma in patients with HCV-related cirrhosis.

Nahon P, Sutton A, Rufat P, Charnaux N, Mansouri A, Moreau R, Ganne-Carrié N, Grando-Lemaire V, N'Kontchou G, Trinchet JC, Pessayre D, Beaugrand M.

J Hepatol. 2012 Feb;56(2):426-32. doi: 10.1016/j.jhep.2011.08.010. Epub 2011 Sep 8.

PMID:
21907168
41.

Bone mineral density assessed by dual-energy X-ray absorptiometry in patients with viral or alcoholic compensated cirrhosis. A prospective study.

Mahmoudi A, Sellier N, Reboul-Marty J, Chalès G, Lalatonne Y, Bourcier V, Grando V, Barget N, Beaugrand M, Trinchet JC, Ganne-Carrié N.

Clin Res Hepatol Gastroenterol. 2011 Nov;35(11):731-7. doi: 10.1016/j.clinre.2011.07.009. Epub 2011 Aug 27.

PMID:
21873139
42.

Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients.

Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, Ganne-Carrie N, Grando-Lemaire V, Vicaut E, Trinchet JC, Beaugrand M.

J Clin Endocrinol Metab. 2011 Aug;96(8):2601-8. doi: 10.1210/jc.2010-2415. Epub 2011 Jul 13.

PMID:
21752887
43.

Survival after radiofrequency ablation and salvage transplantation in patients with hepatocellular carcinoma and Child-Pugh A cirrhosis.

N'Kontchou G, Aout M, Laurent A, Nahon P, Ganne-Carrié N, Grando V, Baghad I, Roulot D, Trinchet JC, Sellier N, Cherqui D, Vicaut E, Beaugrand M, Seror O.

J Hepatol. 2012 Jan;56(1):160-6. doi: 10.1016/j.jhep.2011.03.026. Epub 2011 May 19.

PMID:
21703186
44.

Chemokine RANTES promoter dimorphisms and hepatocellular carcinoma occurrence in patients with alcoholic or hepatitis C virus-related cirrhosis.

Charni F, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, Ganne-Carrié N, Trinchet JC, Beaugrand M, Charnaux N, Nahon P.

Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1439-46. doi: 10.1158/1055-9965.EPI-11-0341. Epub 2011 May 24.

45.

Metabolomic approach by 1H NMR spectroscopy of serum for the assessment of chronic liver failure in patients with cirrhosis.

Amathieu R, Nahon P, Triba M, Bouchemal N, Trinchet JC, Beaugrand M, Dhonneur G, Le Moyec L.

J Proteome Res. 2011 Jul 1;10(7):3239-45. doi: 10.1021/pr200265z. Epub 2011 Jun 2.

PMID:
21568267
46.

Telomerase gene mutations are associated with cirrhosis formation.

Hartmann D, Srivastava U, Thaler M, Kleinhans KN, N'kontchou G, Scheffold A, Bauer K, Kratzer RF, Kloos N, Katz SF, Song Z, Begus-Nahrmann Y, Kleger A, von Figura G, Strnad P, Lechel A, Günes C, Potthoff A, Deterding K, Wedemeyer H, Ju Z, Song G, Xiao F, Gillen S, Schrezenmeier H, Mertens T, Ziol M, Friess H, Jarek M, Manns MP, Beaugrand M, Rudolph KL.

Hepatology. 2011 May;53(5):1608-17. doi: 10.1002/hep.24217.

PMID:
21520174
47.

Choosing membrane mimetics for NMR structural studies of transmembrane proteins.

Warschawski DE, Arnold AA, Beaugrand M, Gravel A, Chartrand É, Marcotte I.

Biochim Biophys Acta. 2011 Aug;1808(8):1957-74. doi: 10.1016/j.bbamem.2011.03.016. Epub 2011 Apr 6. Review.

48.

Cytolytic hepatitis possibly related to levonorgestrel/ethinylestradiol oral contraceptive use: 2 case reports.

Elouni B, Ben Salem C, Zamy M, Ganne N, Beaugrand M, Bouraoui K, Biour M.

Ann Pharmacother. 2010 Dec;44(12):2035-7. doi: 10.1345/aph.1P201. Epub 2010 Nov 30. No abstract available.

PMID:
21119102
49.

Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years.

Roulot D, Costes JL, Buyck JF, Warzocha U, Gambier N, Czernichow S, Le Clesiau H, Beaugrand M.

Gut. 2011 Jul;60(7):977-84. doi: 10.1136/gut.2010.221382. Epub 2010 Nov 10.

PMID:
21068129
50.

Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes.

Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, Sandrin L, Miette V.

Ultrasound Med Biol. 2010 Nov;36(11):1825-35. doi: 10.1016/j.ultrasmedbio.2010.07.005. Epub 2010 Sep 27.

PMID:
20870345

Supplemental Content

Loading ...
Support Center